Qiagen Sees Brighter Reimbursement Outlook For Companion Diagnostics
This article was originally published in The Gray Sheet
Personalized health care remains an important growth driver for the diagnostics developer, which is juggling some 15 companion diagnostics projects. The reimbursement landscape for FDA-approved tests is improving, Qiagen says.
You may also be interested in...
Qiagen will co-develop and commercialize a companion diagnostic for AstraZeneca’s Iressa lung-cancer drug under an agreement between the firms. Ortho-Clinical Diagnostics will sell a test system for acute kidney injury. BD nabs 510(k)s for STD assays.
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.